Prime Medicines (PRME) has made encouraging pipeline progress of late and investors will focus on related updates when it reports second-quarter 2024 results next month. Surprise - Reported Earnings Histor The Zacks Consensus Estimate for loss per share in the second quarter is pinned at 40 cents. | --- | --- | --- | --- | --- | |----------------------|----------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | Magnitude Consensus Estimate Trend (60 Days) | | | | | | ...